Stimulating Stakeholders’ Imagination: New Creativity Triggers for Eliciting Novel Requirements

Requirements engineering is a creative process in which stakeholders and engineers work together to create ideas for new products, services and systems. Several techniques have proved to be effective for eliciting creative requirements. Yet, most of these techniques are heavy to implement and require long periods of time to be applied correctly. Few lightweight creativity techniques have been developed for use in requirements engineering. One such lightweight technique is the creativity trigger, which provides simple guidance to stakeholders and engineers to help produce creative requirements. While easy to apply, creativity triggers were derived informally from experience of practitioners and have not been validated in a systematic way. This paper reports design and preliminary validation research, that sought to provide empirical foundations for a more complete set of lightweight creativity triggers, to be used by stakeholders and engineers to quickly and simply generate new and useful requirements on products, services and systems

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract: Background: Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals’ needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. Methods/design: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. Primary outcome: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson’s Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. Discussion: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. Trial registration: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016

Creativity Triggers: Extension and empirical evaluation of their effectiveness during requirements elicitation

Creativity helps organization to produce novel solutions to complex and sometimes enduring problems. By breaking traditional ways of looking at a given problem and facilitating the design of alternative approaches, creativity contributes to the creation of value-adding solutions within an organization. This is true for any type of problem, including the problem of specifying the requirements for a new software or system. A number of creativity methods, techniques and tools have been proposed as a way to be more creative during Requirements Engineering (RE). They are however often demanding in terms of time, human involvement and resources, thereby reducing their attractiveness for RE practitioners and their stakeholders. Our previous research has led to the proposition of a lightweight tool to support creativity in RE; the Creativity Triggers (CTs). CTs are cards to be used during requirements elicitation to foster creativity from stakeholders and help them uncover novel features of a system-to-be. This paper builds on – and extends – our early conceptualization of CTs to produce a more comprehensive and empirically grounded proposal. Our contribution is twofold; first, we conduct a large-scale and systematic exploration of the qualities underlying the CTs. The objective is to improve the completeness of the tool in order to produce a final set of CTs. Second, we conduct a validation of CTs in different contexts and with different viewpoints to evaluate its usefulness in supporting creativity during requirements elicitation. We end-up with a set of 22 CTs that provided evidence for supporting creativity during RE

Thermoplastic elastomers - their possible use as gaiter materials in a radiation environment

SIGLEAvailable from British Library Document Supply Centre- DSC:9091.9(AEA-InTec--0979) / BLDSC - British Library Document Supply CentreGBUnited Kingdo